12 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
The Institute of Cancer Research
Synthesis and biological evaluation of a unique heparin mimetic hexasaccharide for structure-activity relationship studies.
Momenta Pharmaceuticals
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.
Novartis Institutes For Biomedical Research
[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.
Novartis Institutes For Biomedical Research
Improving the solubility and antileukemia activity of Wnt/β-catenin signaling inhibitors by disrupting molecular planarity.
University of Maryland
Arylated camphenes, processes for their preparation and uses thereof
Yissum Research Development Company of The Hebrew University of Jerusalem
In search of new a-glucosidase inhibitors: Imidazolylpyrazole derivatives.
University of The Punjab
Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
Confluence Life Sciences